Cargando…

Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia

Myeloid neoplasms are clonal hematopoietic stem cell disorders driven by the sequential acquisition of recurrent genetic lesions. Truncating mutations in the chromatin remodeler ASXL1 (ASXL1(MT)) are associated with a high-risk disease phenotype with increased proliferation, epigenetic therapeutic r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Binder, Moritz, Carr, Ryan M., Lasho, Terra L., Finke, Christy M., Mangaonkar, Abhishek A., Pin, Christopher L., Berger, Kurt R., Mazzone, Amelia, Potluri, Sandeep, Ordog, Tamas, Robertson, Keith D., Marks, David L., Fernandez-Zapico, Martin E., Gaspar-Maia, Alexandre, Patnaik, Mrinal M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931048/ https://www.ncbi.nlm.nih.gov/pubmed/35301312 http://dx.doi.org/10.1038/s41467-022-29142-6

Ejemplares similares

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Binder, Moritz, et al.
Publicado: (2023)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project
por: Li, Marissa, et al.
Publicado: (2021)

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
por: Patnaik, M M, et al.
Publicado: (2016)

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
por: Carr, Ryan M., et al.
Publicado: (2021)

How I diagnose and treat chronic myelomonocytic leukemia
por: Patnaik, Mrinal M.
Publicado: (2022)

ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
por: Perez Botero, J, et al.
Publicado: (2015)

Blast Phase Chronic Myelomonocytic Leukemia: Mayo-MDACC Collaborative study of 171 cases
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia
por: Lasho, T L, et al.
Publicado: (2015)

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
por: Pophali, Prateek, et al.
Publicado: (2020)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
por: Gangat, Naseema, et al.
Publicado: (2019)

Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia
por: Pophali, Prateek A., et al.
Publicado: (2019)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
por: Kim, Hyun-Young, et al.
Publicado: (2018)

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
por: Tefferi, Ayalew, et al.
Publicado: (2017)

Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling
por: Sandoval, Leticia, et al.
Publicado: (2023)

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
por: Badar, Talha, et al.
Publicado: (2023)

P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
por: Baranwal, A., et al.
Publicado: (2022)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
por: Patnaik, M M, et al.
Publicado: (2017)

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
por: Szuber, Natasha, et al.
Publicado: (2018)

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders
por: Ferrer, Alejandro, et al.
Publicado: (2022)

Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with ASXL1 and EZH2 gene mutations: A case report
por: Deng, Lai-Jun, et al.
Publicado: (2023)

P726: TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA
por: Wang, Yu-Hung, et al.
Publicado: (2023)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia
por: Johnson, Steven M., et al.
Publicado: (2019)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Genetic predictors of response to specific drugs in primary myelofibrosis
por: Penna, Domenico, et al.
Publicado: (2018)

Functional and cancer genomics of ASXL family members
por: Katoh, M
Publicado: (2013)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h5aiaf6538q43b57bdkgagc4dk